Cocrystal Pharma highlights in vitro activity of CC-42344 against avian H5N1, Phase 2a data expected by end of 2024

Cocrystal Pharma, Inc.

CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.
Phase 2a human challenge study for seasonal influenza A topline safety/tolerability results expected by end of 2024.
Phase 1 study of pan-viral candidate CDI-988 for noroviruses and coronaviruses; topline data expected late 2024 or early 2025.
No approved vaccine or antiviral for norovirus; estimated 685M cases and 200K deaths annually worldwide (CDC).
Preparations underway for US IND application for late-stage study of CC-42344.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.